Literature DB >> 35871556

The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: A comparative analysis of the early and current strains.

Rang Liu1,2, Xinran Lin1, Bing Chen1, Zhenhui Hou1, Qiuju Zhang1, Shouren Lin1, Lan Geng1, Zhongyi Sun1, Canhui Cao1,3, Yu Shi1, Xi Xia1.   

Abstract

The surface glycoprotein (S protein) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was used to develop coronavirus disease 2019 (COVID-19) vaccines. However, SARS-CoV-2, especially the S protein, has undergone rapid evolution and mutation, which has remained to be determined. Here, we analyzed and compared the early (12 237) and the current (more than 10 million) SARS-CoV-2 strains to identify the mutation features and geographical distribution of the S gene and S protein. Results showed that in the early strains, most of the loci were with relative low mutation frequency except S: 23403 (4486 strains), while in the current strains, there was a surge in the mutation strains and frequency, with S: 23403 constantly being the highest one, but tremendously increased to approximately 1050 times. Furthermore, D614 (S: 23403) was one of the most highly frequent mutations in the S protein of Omicron as of March 2022, and most of the mutant strains were still from the United States, and the United Kingdom. Further analysis demonstrated that in the receptor-binding domain, most of the loci with low mutation frequency in the early strains, while S: 22995 was nowadays the most prevalent loci with 3 122 491 strains in the current strains. Overall, we compare the mutation features of the S region in SARS-CoV-2 strains between the early and the current stains, providing insight into further studies in concert with emerging SARS-CoV-2 variants for COVID-19 vaccines.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  ACE2-binding region; COVID-19; SARS-CoV-2; genome mutations; surface glycoprotein

Mesh:

Substances:

Year:  2022        PMID: 35871556      PMCID: PMC9350160          DOI: 10.1002/jmv.28023

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   20.693


  37 in total

1.  NGL viewer: web-based molecular graphics for large complexes.

Authors:  Alexander S Rose; Anthony R Bradley; Yana Valasatava; Jose M Duarte; Andreas Prlic; Peter W Rose
Journal:  Bioinformatics       Date:  2018-11-01       Impact factor: 6.937

2.  The COVID-19 vaccine development landscape.

Authors:  Tung Thanh Le; Zacharias Andreadakis; Arun Kumar; Raúl Gómez Román; Stig Tollefsen; Melanie Saville; Stephen Mayhew
Journal:  Nat Rev Drug Discov       Date:  2020-05       Impact factor: 84.694

Review 3.  COVID-19 vaccination: The road ahead.

Authors:  Daniel M Altmann; Rosemary J Boyton
Journal:  Science       Date:  2022-03-10       Impact factor: 47.728

4.  NGL Viewer: a web application for molecular visualization.

Authors:  Alexander S Rose; Peter W Hildebrand
Journal:  Nucleic Acids Res       Date:  2015-04-29       Impact factor: 16.971

Review 5.  Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus.

Authors:  Chean Yeah Yong; Hui Kian Ong; Swee Keong Yeap; Kok Lian Ho; Wen Siang Tan
Journal:  Front Microbiol       Date:  2019-08-02       Impact factor: 5.640

6.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

7.  Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Authors:  Pedro M Folegatti; Mustapha Bittaye; Amy Flaxman; Fernando Ramos Lopez; Duncan Bellamy; Alexandra Kupke; Catherine Mair; Rebecca Makinson; Jonathan Sheridan; Cornelius Rohde; Sandro Halwe; Yuji Jeong; Young-Shin Park; Jae-Ouk Kim; Manki Song; Amy Boyd; Nguyen Tran; Daniel Silman; Ian Poulton; Mehreen Datoo; Julia Marshall; Yrene Themistocleous; Alison Lawrie; Rachel Roberts; Eleanor Berrie; Stephan Becker; Teresa Lambe; Adrian Hill; Katie Ewer; Sarah Gilbert
Journal:  Lancet Infect Dis       Date:  2020-04-21       Impact factor: 25.071

8.  A booster with SARS-CoV-2 vaccines: protection against Omicron infection.

Authors:  Yuehong Hu; Qiu Sun
Journal:  Signal Transduct Target Ther       Date:  2022-04-05

Review 9.  Developments in Viral Vector-Based Vaccines.

Authors:  Takehiro Ura; Kenji Okuda; Masaru Shimada
Journal:  Vaccines (Basel)       Date:  2014-07-29

10.  Amino acid variation analysis of surface spike glycoprotein at 614 in SARS-CoV-2 strains.

Authors:  Liang Huang; Kui Liu; Ke Ma; Yuan Tian; Yu Qin; Haiyin Sun; Wencheng Ding; Lingli Gui; Peng Wu
Journal:  Genes Dis       Date:  2020-06-02
View more
  1 in total

1.  The mutation features and geographical distributions of the surface glycoprotein (S gene) in SARS-CoV-2 strains: A comparative analysis of the early and current strains.

Authors:  Rang Liu; Xinran Lin; Bing Chen; Zhenhui Hou; Qiuju Zhang; Shouren Lin; Lan Geng; Zhongyi Sun; Canhui Cao; Yu Shi; Xi Xia
Journal:  J Med Virol       Date:  2022-08-06       Impact factor: 20.693

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.